[ad_1]
Turkey announced on Thursday (24) that the Coronavac vaccine, developed by the Chinese laboratory Sinovac, is 91.25% effective in preventing Covid-19.
Coronavac was developed by the Chinese laboratory Sinovac
Photo: EPA / Ansa – Brazil
The number is the result of the preliminary analysis of the phase 3 clinical trial carried out in the country, which has already ordered 50 million doses of the immunizer, and the first shipment should arrive next Monday (28).
Turkey initially planned to start its vaccination campaign on December 11, but the delivery of doses ended up being delayed.
In addition to the 91.25% effectiveness, researchers from the government scientific council stated that Coronavac produced no serious side effects, except for an allergic reaction in one volunteer.
“We are now confident that the vaccine is effective and safe for the Turkish people,” said Health Minister Fahrettin Koca. Efficacy data has not yet been independently analyzed.
Saint Paul
The announcement made by Turkey on Thursday contradicts the new position of the São Paulo state government, which is also testing the vaccine and will produce it at the Butantan Institute.
After promising to release the efficacy data on December 15 and then on December 23, João Doria’s management said last Wednesday that the percentage could not be disclosed now because Sinovac wants to unify the numbers from all phase 3 trials.
“We have a contract with Sinovac that specifies that the announcement of this number must be done together, at the same time. We present these numbers to our partner, who, however, requested that they not be disclosed for the reason that he needs to analyze each of the Cases to be able to apply these cases to the NMPA agency, which is Anvisa of China ”, justified the director of Butantan, Dimas Covas.
Despite this, the Secretary of Health of São Paulo, Jean Gorinchteyn, guaranteed that the immunizer reached a sufficient efficacy index to be approved by Anvisa.
See also:
